Drug research and development is often likened to finding a needle in a haystack with multiple targets and many potential variables with which they can interact. So, what technological advancements are impacting development timelines…
In this article, Michael Adeogun, head of Life Sciences and Health at NPL examines how and where measurement can help government and industry grasp the opportunities the Strategy and Sector Deal offer.
Spotting the signs and symptoms of various infectious diseases can mean the difference between life and death. According to research in the journal Epidemiology and Infection, public awareness campaigns are vital in stopping infections spreading
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence has revealed that the UK has the strongest research and development (R&D) pipeline in Europe.
The collaboration between AstraZeneca and TissUse is progressing with the establishment of relevant microphysiological system (MPS) models based on TissUse’s multi-organ-chip technology, the companies announced.
In this online exclusive, Jessica Foreman, freelance writer who works within the life sciences sector, reveals her guide on how to ensure you are maximising value at each stage of product development
A new joint report from the Medicines Discovery Catapult and the UK BioIndustry Association (BIA), released today (Thursday 18 January) has revealed insights into the productivity of the UK’s drug discovery community.
Dr Liz Covey-Crump director of Business Development at Lhasa Limited describes the opportunities, challenges and trends she has experienced over the course of 2017.
Health systems are facing the biggest challenge in their existence: financial sustainability fuelled by the costs of prescription drugs. Here, Marisa Miraldo, associate professor at Imperial College Business School, goes into more detail…
Researchers from the University of Aberdeen have shown that a drug being trialled for the treatment of breast cancer and diabetes is capable of ‘melting away’ the fat build up inside arteries that can cause heart attacks and strokes.
Traditionally, excipient selection has been performed using trial-and-error based methodologies, which are time-consuming and expensive. In this article, Dr Amjad Alhalaweh, PhD, formulation scientist, Recipharm, discusses a new method, HTS
